Search

everythinglearnresearchcommunity

for

Search:↓

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.

Removing certain hair follicle stem cells worsens skin reactions to allergens.

Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.

A skin rash after the AstraZeneca COVID-19 vaccine was treated successfully with medication.

The QuantAnts machines can find cancer markers and create CRISPR targets for them.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

3α-AdiolG is a good marker for androgen activity in women with excessive hair growth and decreases with anti-androgen treatment.

Rituximab therapy successfully treated a patient's complete body hair loss and was effective for six years.

S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.

ACTH may be an effective first-line treatment for acute calcium pyrophosphate crystal arthritis.

The AC 2 peptide from Trapa japonica fruit helps protect hair cells and may treat hair loss.

The new ELISA method is reliable and eco-friendly for checking the quality of Pueraria candollei.

The DPCP/HPβCD complex improves solubility and anti-inflammatory effects for alopecia areata treatment.

Adding a second method to PROTACs could improve cancer treatment.

Diphencyprone increases Bcl-2 protein in patients with hair regrowth from alopecia areata.

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

Researchers created 10 new compounds similar to cercidin, which could lead to new antibiotics.

Baricitinib is the most effective treatment for alopecia areata.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.

The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.